L.A. YAGUDINA

Kazan State Medical Academy, 36 Butlerova St., Kazan, Russian Federation 420012

Yagudina L.A. — Cand. Med. Sc., Assistant Professor of the Department of Clinical Pathology, tel. (843) 236-09-09, e-mail: yagudinaleila@mail.ru

This article presents data analysis of the literature on the use of various laboratory markers in the prediction of cervical cancer (CC). Human papilloma virus (HPV) plays a key role in the development of cervical cancer. Special attention is paid to the identification of nucleic acids of HPV, viruses genotyping in accordance with the level of oncogenicity, identification of virus prediction proteins of development of malignant growth and identification of damaged cellular factors for predicting cervical cancer. Comparative analysis of laboratory methods of diagnosis this markers is given here. Worth and limitations in use of this markers in prognosis of cervical cancer are discussed.

Key words: human papilloma virus (HPV), cervical cancer.

 

REFERENCES

1. Ogilvie G.S., van Niekerk D.J. et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design preliminary results. BMC Cancer, 2010, no. 2. 111 p.

2. McCredie M.R., Sharples K.J. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol., 2008, no. 2, pp. 425-34.

3. Nazarova E.L., Yovdiy A.V. Treatment of patients with latent papillomavirus infection. Voprosy ginekologii, akusherstva i perinatologii, 2008, vol. 7, no. 5, pp. 47-51 (in Russ.).

4. Kiselev V.I., Kiselev O.I. VPCh v razvitii raka sheyki matki [HPV in cervical cancer development]. Moscow, 2006. 80 p.

5. Peirson L., Fitzpatrick-Lewis D. et al. Screening for cervical cancer. Hamilton, ON: McMaster Evidence Review and Synthesis Centre, 2012.

6. Sasieni P., Castanon A. et al. Screening and adenocarcinoma of the cervix. Int.J.Cancer., 2009, no. 2, pp. 525-29.

7. Higgins J.P.T., Altman D.G. In: Cochrane Handbook for systematic Reviews of interventions. West Sussex, UK: Wiley, 2008, pp. 297-333.

8. Kiselev V.I., Kiselev O.I. Etiological role of human papillomavirus in cervical cancer development: genetic and pathogenic mechanisms. Tsitokiny i vospalenie, 2003, vol. 2, no. 4, pp. 31-38 (in Russ.).

9. Novik V.I. Epidemiology of cervical cancer risk factors, screening. Prakticheskaya onkologiya, 2002, vol. 3, no. 3, pp. 156-165 (in Russ.).

10. Vesco K.K., Witlock E.P. et al. Screening for cervical cancer: a systematic evidence review for the US. Preventive services nask force. Rockville, MD: Agency for healthcare research and quality (US), 2011.

11. Andrae B., Kemetli L. et al Screening-preventable cervical cancer risks: evidence from a nationwideaudit in Swede. J.Natl. Cancer Inst., 2008, no. 2, pp. 622-29.

12. Leonov M.G. Improving cytological diagnosis of cervical cancer. Kubanskiy nauchno-meditsinskiy vestnik, 2010, no. 6, pp. 75-78 (in Russ.).

13. Decker K., Demers A. et al. Papanicolaou test utilization and frequency of screening opportunities among women diagnosed with cervical cancer. Open Med., 2009, no. 2, e140-47.

14. Zappa M., Visioli C.B. et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br.J.Cancer, 2004, no. 2, pp. 1784-86.

15. Sasieni P., Castanon A. et al. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ, 2009, no. 2, b2968.

16. Rebolj M., van Ballegooijen M. et al. Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ, 2009, no. 2, b1354.

17. Sterne J.A.C., Egger M. et al. In: Cochrane handbook for systematic reviews of interventions. Higgins J.R.T., Green S., editor. West Sussex, UK, Wiley. 2008. Pp. 297-333.

18. Novik V.I. Cervical cancer screening. Prakticheskaya onkologiya, 2010, vol. 11, no. 2, pp. 66-73 (in Russ.).

19. Sasieni P., Adams J. et al. Benefit of cervical screening at different ages: evidence from UK audit of screening histories. Br.J.Cancer, 2003, no. 2, pp. 288-93.

20. Puccala E., Coebergh J.W.W. et al. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int. J. Cancer, 2008, 2, pp. 1854-58.

21. Sankaranarayanan R., Nene B.M. et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med., 2009, 2, pp. 1385-94.

22. Miller M.G., Sung H.Y. et al. Screening interval and risk of invasive squamous cell cervical cancer. Obstet. Gynecol. 2003, 2, pp. 29-37.

23. Guyatt G.H., Oxman A.D. et al. GRADE: an emerging consensus on rating quality of evidence and strenght of recommendations. BMJ, 2008, no. 2, pp. 924-26.

24. Prikaz Minzdrava SSSR №1253 ot 30.12.76 “O merakh po uluchsheniyu tsitologicheskoy diagnostiki zlokachestvennykh novoobrazovaniy” [Order of the USSR Ministry of 30.12.76 № 1253 “On measures to improve the cytological diagnosis of malignant tumors”].

25. Kasinpila C., Promthet S. et al. Evaluation of the nationwide cervical screening program in Thailand: a case-control study. J. Med. Screen, 2011, no. 2, pp. 147-53.